RedChip Companies

📅 1 Week to Go: Don’t miss 60 Degrees Pharmaceuticals, INC (Nasdaq: SXTP) Live Investor Webinar on Oct. 22 at 4:15 PM EST. 🎯 Learn about pipeline growth, market expansion, and key milestones. 🔗 Register Here: https://bit.ly/4mtaWn6 PharmaVoice Genetic Engineering & Biotechnology News Biotechnology #SXTP #BiotechInvesting #Webinar

Investors: Learn how 60 Degrees is advancing infectious disease treatments with its FDA-approved malaria drug ARAKODA® and a growing pipeline targeting babesiosis and other emerging threats. Hear the latest on 60P’s strategy, pipeline, and market potential.

🧬 Aptevo Therapeutics Inc (Nasdaq: APVO): 100% Remission in Cohort 3 Reinforces Mipletamig’s Differentiated Position in AML Aptevo Therapeutics Inc announced a 100% remission rate (CR/CRi) in Cohort 3 of its RAINIER trial evaluating mipletamig, its first-in-class CD123 x CD3 bispecific antibody, in combination with venetoclax + azacitidine for newly diagnosed AML patients unfit for intensive chemotherapy. Crucially, no dose-limiting toxicities or cytokine release syndrome (CRS) have been observed to date across the trial. 📊 Why It Matters: • High-Impact Efficacy: 100% remission in Cohort 3, with 40% of patients achieving MRD-negative status, a key marker for long-term remission and survival in AML. • Consistent Safety Profile: No CRS or dose-limiting toxicities across three dose levels in RAINIER and prior studies, supporting mipletamig's use in combination regimens. • Compelling Market Opportunity: Frontline AML remains a multibillion-dollar global market with high unmet need and limited innovation in patients unfit for intensive chemo. 🔗 Learn more: https://bit.ly/3H6BN9S PharmaVoice Genetic Engineering & Biotechnology News Biotechnology #BiotechStocks #AML #ClinicalTrials #CancerResearch #Aptevo #APVO #Oncology

🎙️ BullFrog AI Exclusive Interview with CEO Vin Singh: Unlocking the Future of AI in Drug Discovery BullFrog AI (Nasdaq: BFRG) is changing the game for drug development, and CEO Vin Singh breaks down how in this must-watch interview. From their proprietary bfLEAP® technology to the launch of BullFrog Data Networks®, hear how the company is accelerating clinical breakthroughs and driving smarter R&D decisions, especially for small and mid-sized biopharma players. 💡 Why Investors Should Tune In: 📊 Addressing a $204B+ R&D Market with scalable AI tools that cut costs and timelines 🤝 Strategic partnerships with world-class institutions like the J. Craig Venter Institute 🔬 Dual-revenue model: AI-powered platforms + advancing licensed drug assets 🎯 With only 12% of drugs reaching market post-Phase 1, BullFrog's precision-driven approach could be a major differentiator in biotech investing. 📺 https://bit.ly/4573Qhf Lieber Institute for Brain Development J. Craig Venter Institute PharmaVoice Genetic Engineering & Biotechnology News Biotechnology #BFRG #AIinBiotech #DrugDiscovery #BiopharmaInnovation #InvestorInsights #VinSingh #BullFrogAI #FinancialNews

📺 FatPipe Networks: Watch our 30-Second Investor Overview FatPipe Networks (Nasdaq: FATN), a pioneer in secure networking, is scaling its enterprise-grade SD-WAN and SASE solutions across North America and Southeast Asia. 💡 Key Highlights for Investors: ✅ FY24 Revenue: $17.9M | Net Income: $4.4M (24.4% margin) ✅ 2,500+ customers across government, finance, healthcare, and retail ✅ Expanding footprint in Southeast Asia & Mexico ✅ Positioned in a $49B+ market growing at double-digit CAGR With patented technology, a 90%+ gross margin SaaS model, and proven profitability, FatPipe offers exposure to cutting-edge, mission-critical enterprise networking. 🎥 Watch the 30-second video here: https://bit.ly/4pKSbOD TechCrunch #FATN #TechStocks #Networking #Cybersecurity #FinancialNews

Top scientists and Pfizer’s former CMO are backing Calidi Biotherapeutics (NYSE American: CLDI). Why? Because its systemic genetic delivery platform could redefine how we treat cancer. 🎥 Watch our 30-sec investor overview. 🔗 https://lnkd.in/emQsAcmh California Institute for Regenerative Medicine (CIRM) Northwestern University City of Hope The Lancet Group PharmaVoice Genetic Engineering & Biotechnology News #CLDI #Biotech #Investing #Oncology #GeneticMedicine